BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it received a second $100,000 award from the State of Maryland Industrial Partnerships (MIPS) program after successful completion of the first year’s research goals. The Company is working with the University of Maryland, Baltimore (UMB) to develop a novel pharmaceutical product specifically aimed at preventing reperfusion injury associated with cardiac ischemia (heart attack). RegeneRx is contributing approximately $54,000 and retains the right to exclusively license all intellectual property developed under the project.
